Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL681121 | 1.00 | CYP2C9 (0.35) | CYP2C9TSHRCYP2C19TDP1OPRD1 | |
| SCHEMBL2760276 | 1.00 | CYP2C9 (0.35) | CYP2C9TSHRCYP2C19TDP1OPRD1 | |
| SCHEMBL14085840 | 1.00 | CYP2C9 (0.35) | CYP2C9TSHRCYP2C19TDP1OPRD1 | |
| SCHEMBL21444359 | 1.00 | CYP2C9 (0.35) | CYP2C9TSHRCYP2C19TDP1OPRD1 | |
| SCHEMBL25105674 | 0.84 | — | — | |
| SCHEMBL21074961 | 0.84 | — | — | |
| SCHEMBL16491200 | 0.84 | — | — | |
| SCHEMBL25105676 | 0.84 | — | — | |
| SCHEMBL14085842 | 0.84 | CYP2C9 (0.39) | CYP2C9TSHRCYP2C19TDP1 | |
| SCHEMBL25097034 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11827646-B2 | Compounds for treating spinal muscular atrophy | HOFFMANN-LA ROCHE INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-11827646-B2 | Compounds for treating spinal muscular atrophy | HOFFMANN-LA ROCHE INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-20230227470-A1 | ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | VANDERBILT UNIVERSITY | 2023-07-20 | — | — | US | disclosed |
| WO-2023099624-A1 | ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-06-08 | — | — | WO | disclosed |
| WO-2022058745-A9 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AND THEIR USE IN THERAPY | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2022-05-27 | — | — | WO | disclosed |
| WO-2022058745-A2 | NOVEL COMPOUNDS AND THEIR USE IN THERAPY | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2022-03-24 | — | — | WO | disclosed |
| US-20210147447-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | HOFFMANN-LA ROCHE INC. (US) | 2021-05-20 | — | — | US | disclosed |
| WO-2020035031-A1 | FUSED RING COMPOUNDS | GENENTECH, INC. (US) | 2020-02-20 | — | — | WO | disclosed |
| EP-3298017-B1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | HOFFMANN LA ROCHE (CH) | 2019-08-14 | — | — | EP | disclosed |
| EP-3160967-B1 | N-(IMIDAZO[1,2-A]PYRAZIN-6-YL)-BENZAMIDE COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | HOFFMANN LA ROCHE (CH) | 2019-05-08 | — | — | EP | disclosed |
| US-10208067-B2 | Compounds for treating spinal muscular atrophy | HOFFMANN-LA ROCHE INC. (US) | 2019-02-19 | — | — | US | disclosed |
| US-20180194781-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | HOFFMANN-LA ROCHE INC. (US) | 2018-07-12 | — | — | US | disclosed |
| US-20180194781-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | HOFFMANN-LA ROCHE INC. (US) | 2018-07-12 | — | — | US | disclosed |
| US-9975900-B2 | Substituted imidazo[1,2-α]pyrazines for treating spinal muscular atrophy | HOFFMANN-LA ROCHE INC. (US) | 2018-05-22 | — | — | US | disclosed |
| US-9969754-B2 | Compounds for treating spinal muscular atrophy | HOFFMANN-LA ROCHE INC. (US) | 2018-05-15 | — | — | US | disclosed |
| US-20170197990-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | HOFFMANN-LA ROCHE INC. (US) | 2017-07-13 | — | — | US | disclosed |
| US-20170197969-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | HOFFMANN-LA ROCHE INC. (US) | 2017-07-13 | — | — | US | disclosed |
| US-20170197969-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | HOFFMANN-LA ROCHE INC. (US) | 2017-07-13 | — | — | US | disclosed |
| US-20170197990-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | HOFFMANN-LA ROCHE INC. (US) | 2017-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227470-A1 | ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | KRAS, NRAS, TP53 | CYP2C9 1828/4885TSHR 1257/4885CYP2C19 1386/4885 |
| US-20210147447-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | SMN1; SMN2, CPT1B, GYS1 | CYP2C9 4505/4885TSHR 3021/4885CYP2C19 3934/4885 |
| US-20170197990-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | SMN1; SMN2, CPT1B, GYS1 | CYP2C9 4505/4885TSHR 3021/4885CYP2C19 3934/4885 |
| US-20180194781-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | SMN1; SMN2, PYGM, CPT1B | CYP2C9 4518/4885TSHR 3123/4885CYP2C19 4028/4885 |
| US-11827646-B2 | Compounds for treating spinal muscular atrophy | SMN1; SMN2, CPT1B, GYS1 | CYP2C9 4505/4885TSHR 3021/4885CYP2C19 3934/4885 |
| US-20170197969-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | SMN1; SMN2, PYGM, GYS1 | CYP2C9 3794/4885TSHR 2674/4885CYP2C19 3037/4885 |
| US-10208067-B2 | Compounds for treating spinal muscular atrophy | SMN1; SMN2, PYGM, CPT1B | CYP2C9 4518/4885TSHR 3123/4885CYP2C19 4028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.